maps • volume xvi number 3 • Winter 2006-7

ECSTASY and Cheerleading:
A Basic Risk Comparison

Jag Davies

A January 8, 2006 Boston Globe article, “The Most Dangerous Sport in School,” reported on several instances of catastrophic, sometimes deadly, cheerleading accidents. Apparently, like taking prescription medications, living in a polluted city, and driving a car, recreational sports such as cheerleading are activities that our society views as having serious, but acceptable, risks. How, then, does this compare historically to the risks society deems as unacceptable, such as those associated with the recreational use of Ecstasy? I did some research to find out.

I focused on Emergency Room (ER) visit data, the most common indicator of cost to public health. For example, according to the Drug Abuse Warning Network (DAWN), in 1994–nine years after MDMA was criminalized, but the first for which data is available from SAMHSA– there were 253 ER visits as a result of Ecstasy use in the US. Meanwhile, according to the US Consumer Product Safety Commission (USCPSC), in 1994 there were 15,792 ER visits as a result of participation in organized cheerleading. By that measure, in 1994 cheerleading was 62 times more of a threat to our nation’s public health than Ecstasy use. Keep in mind that most users don’t know whether their Ecstasy is pure MDMA, so these statistics reflect the risks of using unregulated black-market Ecstasy, which often contains other substances and sometimes does not even contain MDMA.

 

Cheerleading Ecstasy Risk Comparison Chart

In 2001, when past-year Ecstasy use reached its peak, the total number of pastyear cheerleaders (3.8 million) and Ecstasy users (3.25 million) were relatively similar1. Still, past-year participation in organized cheerleading was four and a half times more likely than pastyear use of Ecstasy to have caused a medical crisis necessitating a visit to ER.

To look at those numbers another way, in 2001, one out of every 152 organized cheerleading participants sought ER treatment, while only one of out of every 585 past-year Ecstasy users sought ER treatment. Note that this data does not account for the differences between users; a cheerleader who practices daily and an Ecstasy user who takes the drug once a month are both counted here simply as participants. It is also worth noting that a study of ER admissions in the Netherlands found that most patients (89%) with an Ecstasy-related complaint did not require treatment beyond the initial visit with a doctor2.

In 2003, DAWN implemented a new methodology for calculating drug-related ER visits, and my estimate of 4,442 for that year is based on the only data available, an interim estimate from July- December 2003 of 2,221. In 2004, once the “new” DAWN had been implemented, their estimate for Ecstasy-related ER visits nearly doubled to 8,621, much higher than the previous high of 5,542 in 2001, but still a far cry from the whopping 28,414 cheerleading-related ER visits that year. DAWN recommends not comparing the “old” DAWN to the “new” DAWN3, but, taking this into consideration, the “old” DAWN is still valuable data, in fact the only data, available for 1994-2003.

Just Say No to Cheerleading?

Do these statistics mean that cheerleading should join Ecstasy in the shadowy underground of prohibited activities? Most would argue that cheerleading offers benefits that balance its risks, and that with careful preparation and education, these benefits make the risk of injury an acceptable one, even for young people. Unfortunately, the public debate on Ecstasy is limited by both an exaggeration of risks and a silence on benefits. Without a clear look at the actual impact of its use on individuals and on society, the costly decision to prohibit Ecstasy is difficult to justify.

 

Most would argue that cheerleading offers benefits that balance its risks…

 

As mentioned earlier, most of the risks associated with Ecstasy are a direct consequence of prohibitionist public policy. These risks include poor access to realistic harm-reduction educational materials, health risks related to ingesting unregulated material, and delay in medical treatment due to fear of criminal prosecution, imprisonment, stigma, and employment discrimination. Even in rare situations when Ecstasy does cause acute health-related problems and/or dependence, abuse, or addiction, prohibition accentuates these problems.

The economic cost of prohibition of certain drugs is also risky public policy, as billions of dollars are spent every year on propaganda, law enforcement, mandatory treatment, and prisons, forgoing billions of dollars from regulation and taxation that could be spent on honest education, voluntary treatment, and other pressing societal needs. Instead, these billions of dollars fuel underground criminal networks while squandering precious government credibility.

Most relevant to MAPS’ mission is the risk that MDMA’s potential therapeutic benefits will be lost on our society. While young people can still access street Ecstasy almost as easily as taking cheerleading lessons, prohibition has delayed for decades our ability to investigate MDMA’s potential as a medicine and a tool for healing. •

Also, see this interesting review of cheerleading and its dangers from the Washington Post entitled "Rooting for Safety: Cheerleading Is Risky But Ill-Regulated" (2008).

  1. “Past-year” refers to someone who has participated in organized cheerleading or consumed Ecstasy at least once in the past year.
     
  2. Spruit, I.P. “Ecstasy use and policy responses in the Netherlands.” Journal of Drug Issues, 1999; 29(3): 653-678.
     
  3. “New DAWN: Why It Cannot Be Compared with Old DAWN” explains this in greater detail: http://dawninfo.samhsa.gov/pubs/ shortreports/
Summer 2009 Vol. 19, No. 2 MAPS Research Update 2009
Spring 2009 Vol. 19, No. 1 Special Edition: Psychedelics and Ecology
Winter 2008/09 Vol. 18, No. 3 MAPS 2008 Financial Report
Summer 2008 Vol. 18, No. 2 Phoenix Rising: A Review of MAPS Research
Spring 2008 Vol. 18, No. 1 Special Edition: Technology and Psychedelics
Winter 2007 Vol. 17, No. 3 MAPS 06-07 Fiscal Yearly Report
Autumn 2007 Vol. 17, No. 2 Special Edition: Psychedelics and Self-Discovery
Spring/Summer 2007 Vol. 17, No. 1 The Chrysalis Stage
Winter 2006-7 Vol. 16, No. 3 Low Maintenance/High Performance
Autumn 2006 Vol. 16, No. 2 Technologies of Healing
Spring 2006 Vol. 16, No. 1 MAPS' 20th Anniversary
Winter 2005 Vol. 15, No. 3 MAPS final year as a teenager
Summer 2005 Vol. 15, No. 2 Israel Conference: MDMA/PTSD Research
Spring 2005 Vol. 15, No. 1 Accelerating flow of work and time
Autumn 2004 Vol. 14, No. 2 Rites of Passage: Kids and Psychedelics
Summer 2004 Vol. 14, No. 1 10 stamps and $250,000
Winter 2003 Vol. 13, No. 2 Holy Fire
Spring 2003 Vol. 13, No. 1 60th Anniversary of the Discovery of LSD
Autumn 2002 Vol. 12, No. 3 Vision
Summer 2002 Vol. 12, No. 2 "From celebration to frustration, and back again."
Spring 2002 Vol. 12, No. 1 Sex, Spirit & Psychedelics 2002
Autumn 2001 Vol. 11, No. 2 "In the future, it will be called Despair."
Spring 2001 Vol. 11, No. 1 "A Tidal Wave of Ecstasy!"
Autumn 2000 Vol. 10, No. 3 Creativity 2000
Summer 2000 Vol. 10, No. 2 Endings and Beginnings
Spring 2000 Vol. 10, No. 1 Making History in Slow Motion
Winter 1999/00 Vol. 9, No. 4 To the Ends of the Earth for MDMA Research...
Autumn 1999 Vol. 9, No. 3 MAPS' long-standing efforts to conduct...
Summer 1999 Vol. 9, No. 2 MAPS has come full circle...
Spring 1999 Vol. 9, No. 1 Patience, persistence and passion
Winter 1998/99 Vol. 8, No. 4 One of special pleasures of directing MAPS...
Autumn 1998 Vol. 8, No. 3 The Ayahuasca Issue (with Hofmann interview)
Summer 1998 Vol. 8, No. 2 Emotionally Powerful Anecdotes...
Spring 1998 Vol. 8, No. 1 Death Has a Way of Focusing One's Attention
Autumn 1997 Vol. 7, No. 4 Celebration is in Order
Summer 1997 Vol. 7, No. 3 Time Horizons
Spring 1997 Vol. 7, No. 2 Synchronicity
Winter 1996/97 Vol. 7, No. 1 Learning to Crawl
Autumn 1996 Vol. 6, No. 4 An Invitation for Dialogue
Summer 1996 Vol. 6, No. 3 Budding Research
New Year 1996 Vol. 6, No. 2 Sending Down Roots
Autumn 1995 Vol. 6, No. 1 Baby Steps
Summer 1995 Vol. 5, No. 4 Opportunity Amidst Obstacles
Winter 1994/95 Vol. 5, No. 3 Clinical Trials and Tribulations
Autumn 1994 Vol. 5, No. 2 Building Towards Clinical Trials
Summer 1994 Vol. 5, No. 1 Politics and Protocols: In Search of a Balance
Spring 1994 Vol. 4, No. 4 Laying the Groundwork
Winter 1993/94 Vol. 4, No. 3 A Time of Tests
Summer 1993 Vol. 4, No. 2 So Close Yet So Far
Spring 1993 Vol. 4, No. 1 Remembrance and Renewal
Winter 1992/93 Vol. 3, No. 4 Forging New Alliances
Summer 1992 Vol. 3, No. 3 Building on Common Ground
Spring 1992 Vol. 3, No. 2 Small Steps, Gradual Progress, New Opportunities
Winter 1991/92 Vol. 3, No. 1 The Rekindling of a Thousand Points of Light
Summer 1991 Vol. 2, No. 2 MDMA protocol development with cancer patients
Winter 1990/91 Vol. 2, No. 1 MAPS' Swiss pharmacologically-assisted psychotherapy conference
Autumn 1990 Vol. 1, No. 3 What and Who is MAPS?
Summer 1989 Vol. 1, No. 2 Switzerland Leads the Way
Summer 1988 Vol. 1, No. 1 MDMA can become a legal medicine